Daiwa Securities Group Inc. Grows Holdings in DexCom, Inc. (NASDAQ:DXCM)

Daiwa Securities Group Inc. grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 5.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 80,979 shares of the medical device company's stock after buying an additional 3,880 shares during the quarter. Daiwa Securities Group Inc.'s holdings in DexCom were worth $6,298,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Forvis Mazars Wealth Advisors LLC increased its stake in DexCom by 0.7% in the fourth quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company's stock valued at $1,359,000 after acquiring an additional 118 shares during the last quarter. Principal Securities Inc. boosted its holdings in shares of DexCom by 3.4% in the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock worth $316,000 after purchasing an additional 135 shares in the last quarter. Larson Financial Group LLC boosted its holdings in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after purchasing an additional 137 shares in the last quarter. Crossmark Global Holdings Inc. increased its position in shares of DexCom by 1.0% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company's stock valued at $1,259,000 after purchasing an additional 182 shares during the last quarter. Finally, GPS Wealth Strategies Group LLC raised its holdings in shares of DexCom by 13.2% during the 4th quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company's stock valued at $123,000 after buying an additional 185 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the company's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of the firm's stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares of the company's stock, valued at $7,259,244.66. This represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 45,083 shares of company stock worth $3,826,604. 0.30% of the stock is owned by corporate insiders.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $70.76 on Thursday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company's 50-day moving average is $84.39 and its 200 day moving average is $76.93. The stock has a market capitalization of $27.65 billion, a P/E ratio of 49.48, a P/E/G ratio of 2.30 and a beta of 1.28.

Remove Ads

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, sell-side analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on DXCM shares. Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a research report on Saturday. Morgan Stanley increased their target price on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a report on Friday, February 14th. Robert W. Baird raised shares of DexCom from a "neutral" rating to an "outperform" rating and boosted their price target for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Citigroup raised their price objective on DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research note on Tuesday, March 4th. Finally, Canaccord Genuity Group lifted their price objective on DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $99.82.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.